



## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 5 :  A61K 37/02, 37/66		A1	(11) International Publication Number: <b>WO 93/06847</b>  (43) International Publication Date: 15 April 1993 (15.04.93)		
(21) International Application Number: PCT/US92/08479		(74) Agents: DREGER, Ginger, R. et al.: Genentech, Inc., 460 Point San Bruno Boulevard, South San Francisco, CA 94080-4990 (US).			
(22) International Filing Date: 5 October 1992 (05.10.92)		(81) Designated States: AU, CA, FI, HU, JP, KP, KR, NO, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, SE).			
(30) Priority data: 773/382 7 October 1991 (07.10.91) US		Published <i>With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>			
(71) Applicant: GENENTECH, INC. [US/US]: 460 Point San Bruno Boulevard, South San Francisco, CA 94080-4990 (US).					
(72) Inventors: CZARNIECKI, Christine ; 2667 16th Avenue, San Francisco, CA 94116 (US). KLEIN, Jon, B. ; 6719 Sycamore Woods Drive, Louisville, KY 40207 (US). SLATER, A., David ; 14 River Hill Road, Louisville, KY 40207 (US). SONNENFELD, Gerald ; 2110 Boulevard Napoleon, Louisville, KY 40205 (US).					
(54) Title: USE OF IFN-GAMMA FOR THE TREATMENT OF INFECTIONS IN TRANSPLANT RECIPIENTS					
(57) Abstract					
The invention relates in general to the prevention and treatment of microbial infections in transplant patients. More particularly, the invention concerns the use of lymphokines, and specifically gamma interferon (IFN- $\gamma$ ) for the prophylaxis and treatment of microbial infections in transplant recipients, without increasing the incidence of graft rejections.					

*FOR THE PURPOSES OF INFORMATION ONLY*

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT

AT	Austria	FR	France	MR	Mauritania
AU	Australia	GA	Gabon	MW	Malawi
BB	Barbados	GB	United Kingdom	NL	Netherlands
BE	Belgium	GN	Guinea	NO	Norway
BF	Burkina Faso	GR	Greece	NZ	New Zealand
BC	Bulgaria	HU	Hungary	PL	Poland
BJ	Benin	IE	Ireland	PT	Portugal
BR	Brazil	IT	Italy	RO	Romania
CA	Canada	JP	Japan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	LI	Liechtenstein	SK	Slovak Republic
CI	Côte d'Ivoire	LK	Sri Lanka	SN	Senegal
CM	Cameroun	LU	Luxembourg	SU	Soviet Union
CS	Czechoslovakia	MC	Monaco	TD	Chad
CZ	Czech Republic	MG	Madagascar	TC	Togo
DE	Germany	ML	Malta	UA	Ukraine
DK	Denmark	MN	Mongolia	US	United States of America
ES	Spain			VN	Viet Nam
FI	Finland				

USE OF IFN-GAMMA FOR THE TREATMENT  
OF INFECTIONS IN TRANSPLANT RECIPIENTSField of the Invention

5 The present invention relates in general to the prevention and treatment of microbial infections in transplant patients. More particularly, the invention concerns the use of lymphokines, and specifically gamma interferon (IFN- $\gamma$ ) for the prophylaxis and treatment of microbial infections in transplant recipients, without increasing the incidence of graft rejections.

Background of the Invention

10 It is well established in clinical experience that complications due to infections subsequent to allografting may result in the rejection of the allograft. The transplant patients of ten acquire microbial infections during their hospitalization or suffer infections attributable to microorganisms already colonizing the patient when admitted to the hospital. Microbial infection is considered to be a major limiting factor to the success of transplantation. This 15 is particularly so because the immunosuppression required to prevent graft rejection greatly limits the success of conventional antimicrobial treatment in overcoming infections in transplant patients [Rolston *et al.*, Hospital Formul. 22, 710 (1987); Glenn *et al.*, Rev. Infec. Dis. 10, 42 (1988); Young, L.S., J. Infec. Dis. 147, 611 (1983); Delgado *et al.*, South Med. J. 73, 627 (1980); Schimpff, S.C., In: Current Concepts in Antibiotic Therapy for Febrile 20 Episodes in Neutropenic Patients, page 7, Eli Lilly and Co., Indianapolis, IN (1983)].

One possible way to control microbial infections in transplant recipients would be to use biological response modifiers (immunomodulators) to augment the immune response. This approach has been successfully carried out in animal models of trauma/infection not associated with transplantation, using IFN- $\gamma$  treatment. Rodents that were subjected to 25 several different models of trauma were immunosuppressed and showed increased mortality when infected with a variety of bacteria. Prophylaxis or therapy of the rodents with murine gamma interferon resulted in enhanced survival in several of the models. [Hershman *et al.*, Microb. Pathogen. 4, 165 (1988); J. Interferon Res. 8, 367 (1988); Clin. Exp. Immunol. 73, 406 (1988); and Infec. Immun. 56, 2412 (1988); Livingston, D.H. & Malangoni, M.A., J. 30 Surg. Res. 45, 37 (1988). However, there are strong indications against using IFN- $\gamma$  treatment to control infections in transplant patients.

It is known that cell membrane molecules encoded by genes of the major histocompatibility complex play an essential role in the interaction between cells of the immune system and a transplanted organ [Thorsby, E.; Transplant Proc. 17, 29 (1987)]. 35 Specifically, major histocompatibility complex (MHC) molecules of allografted tissue have the capacity to induce strong immune responses by activating T cells of the recipients. MHC class II molecules appear to be particularly strong transplantation antigens [Klempnauer, *et al.*, Transplant Proc. 17, 1987 (1985)]. Since immunomodulation with IFN- $\gamma$  treatment is

known to include enhanced expression of MHC class II antigens [Interferons and the Immune System, Vilcek, J. & DeMaeyer, Eds., Elsevier Scientific Publishers, B.V., Amsterdam (1985)], there is a valid concern about the use of IFN- $\gamma$  in the treatment of transplant patients. Indeed, IFN- $\gamma$  (just as interleukin-2 (IL-2)) has been implicated as an important mediator of allograft rejection. IFN- $\gamma$  and IL-2 receptor antibodies have been shown to prevent allograft rejection in experimental animals [Landolfo *et al.*, Science **220**, 176 (1985); Rosenberg *et al.*, J. Immunol. **144**, 4648 (1990); Kirkman, R.L. *et al.*, Transplantation **40**, 719 (1985)], and several studies have suggested that lymphokine, and in particular IL-2 and IFN- $\gamma$  production can be correlated with rejection episodes in renal transplant recipients [Yoshimura, N. and Kahan, B.D., Transplantation **40**, 661 (1985); Vie, H. *et al.*, Kidney Int. **28**, 553 (1985); Claesson, K. *et al.*, Transplantation **38**, 32 (1984)]. Woloszczuk *et al.*, J. Clin. Chem. Clin. Biochem. **24**, 729-34 (1986) observed increased serum levels of IFN- $\gamma$  before rejection episodes, either directly related or unrelated to infections, and suggested that this observation would provide an easy and reliable method for monitoring of the immune status of transplant recipients. Systemic interferon administration in renal transplant recipients had been associated with an increased incidence of organ rejections [Kovarik, J. *et al.*, Transplantation **45**, 402 (1988)]. This serious adverse effect was concluded to be a contraindication to the use of interferons in the treatment of renal transplant patients [Baron *et al.*, JAMA **266**, 1375 (1991)].

Although the extent of involvement of lymphokines in graft rejection, and especially the mechanism by which they are involved are far from clear, and some studies of the rejection phenomena following IFN- $\gamma$  therapy have produced contradictory results [McKenna, R.M. *et al.*, Transplantation **45**, 76 (1988); Ijzermans *et al.*, Transplantation **48**, 1039 (1989); Rosenberg *et al.*, supra; Kover *et al.*, Transplantation **49**, 148 (1990); Kover K. and Moore, W.V. in Transplantation Proceedings **22**, 853-85 (1990)], the potential risk of accelerated graft rejection associated with IFN- $\gamma$  administration has so far restrained physicians from using IFN- $\gamma$  to treat infections in transplant patients.

The indications against the administration of lymphokines, and specifically IFN- $\gamma$  to transplant recipients are even more apparent in view of our knowledge about the mechanism of action of cyclosporins and corticosteroids, which are the most commonly used immunosuppressants in transplantation.

The immunosuppressive action of cyclosporins in transplantation has been extensively studied, and is thought to be primarily due to their potent inhibition of lymphokine production by T cells. Cyclosporin A (CsA) has been shown to inhibit the transcription of IFN- $\gamma$  and IL-2 mRNA *in vitro* [Kronke, M. *et al.*, Proc. Natl. Acad. Sci. **81**, 5214 (1984); Elliot *et al.*, Science **226**, 1439 (1984); Granelli-Piperno *et al.*, J. Exp. Med. **163**, 922 (1986)]. Several studies have shown a decrease in interleukin-2 (IL-2) and IFN- $\gamma$  production of renal transplant recipients on cyclosporin A (CsA) treatment. For example, Yoshimura *et al.*, J. Clin.

Immunol. (USA) 9, 322-328 (1989) examined the *in vivo* effect of CsA administered with steroid on the capacity of peripheral blood mononuclear cells (PBMC) from kidney transplant recipients to generate cytokines and their gene expression at mRNA level. They found that combination therapy with CsA and steroid inhibits both IFN- $\gamma$  and IL-2 gene expression.

5        A second, important group of immunosuppressants is the group of corticosteroids (glucocorticoids, GCC). It appears that the most important general cellular mechanisms by which they exert immunosuppressive actions may be their effects on the production and action of soluble factors, such as cytokines [Guyre *et al.*, "Glucocorticoids and the immune system: activation of glucocorticoid-receptor complexes in thymus cells; modulation of Fc receptors of phagocytic cells." In: *Progress in Research and Clinical Applications of Corticosteroids*, Lee, H.J. and Walker, C.A., eds., Heyden & Son, Philadelphia, 14-27 (1981)]. It has also been reported that the production of IFN- $\gamma$  is blocked by glucocorticoids [Guyre, *et al.*, J. steroid Biochem. 14, 35-39 (1981); Kelso, A. and Munck, A., J. Immun. 133, 784-791 (1984)], while several parameters of monocyte activation by IFN- $\gamma$  were either 10 unaffected or enhanced [Girard, *et al.*, J. Immun. 138, 3235-3241 (1987)]. A review of the 15 effects of glucocorticoids on the production and actions of immune cytokines is, for example, provided by Guyre *et al.*, J. steroid Biochem. 30, 89-93 (1988).

20        In summary, although the exact mechanism of the involvement of lymphokines, and specifically IFN- $\gamma$  in graft rejection is not entirely understood, published results raise serious concerns about the applicability of lymphokine, e.g. IFN- $\gamma$  therapy to prevent and fight 25 microbial infection in transplant recipients, and appear to suggest that the potential negative effects of exogenous lymphokine administration could far outweigh any benefit resulting from the treatment of microbial infections.

#### Summary of the Invention

25        The present invention is based on the unexpected finding that lymphokines, and specifically IFN- $\gamma$  can be successfully used for the prophylaxis and treatment of microbial infections in transplant recipients under appropriate conditions, without significant increase in the incidence of rejection episodes. The present inventors have found that under clinical 30 conditions, when following transplantation the transplant recipients are routinely subjected to long-term treatment with low, "maintenance" doses of cyclosporin, microbial infections can be successfully controlled (prevented or treated) by IFN- $\gamma$  administration, without experiencing the potential deleterious effect of IFN- $\gamma$  on graft survival.

35        In one aspect, the present invention relates to a method for the prophylaxis or treatment of microbial infections in transplant recipients comprising administering a therapeutically effective dose of an antimicrobial lymphokine to transplant recipients following transplantation under conditions such that the action of the lymphokine resulting in increased graft rejection is suppressed while retaining its antimicrobial activity. The antimicrobial lymphokine may, for example, be IFN- $\gamma$ , IL-2 or their combination. The antimicrobial

lymphokine is preferably administered to transplant recipients subjected to maintenance immunosuppressive therapy following transplantation. The maintenance immunosuppressive therapy preferably involves the administration of one or more immunosuppressants, such as cyclosporins and/or steroids.

5 In another aspect, the invention concerns a method of avoiding infection-associated graft rejection in transplant recipients, comprising administering a therapeutically effective dose of IFN- $\gamma$  to transplant recipients subjected to maintenance immunosuppressive therapy following transplantation.

Detailed Description of the Invention

10 The term "lymphokine" is used to describe soluble products of lymphoid cells, including proteins secreted by T cells upon activation by antigens or lectins. Examples of lymphokines include, but are not limited to, interferons- $\alpha$ , - $\beta$  and - $\gamma$  (IFN- $\alpha$ , IFN- $\beta$ , IFN- $\gamma$ ), interleukin-2 (IL-2), interleukin-3 (IL-3), tumor necrosis factor- $\alpha$  (TNF- $\alpha$ ), a colony stimulating factor (CSF-1, CSF-G, or CSF-GM), etc. The term "antimicrobial" activity includes antiviral, antibacterial, 15 antiparasitic and antifungal activities. Typical representatives of lymphokines with antimicrobial activity are IFN- $\alpha$ , IFN- $\beta$ , IFN- $\gamma$ , IL-2, and TNF- $\alpha$ . Antimicrobial activity can be tested in established in vitro and in vivo models. Typical in vitro models are based on testing the activation of monocytes or neutrophils, and include the oxidative burst model described in Example 1 [see also Clifford, D.P., Repine, J.E., Methods. Enzymol. 105, 393 (1984)]. In vivo animal (e.g. rodent and non-human primate) models suitable for evaluating the antiviral, 20 antibacterial, antiparasitic, and antifungal activities of lymphokines, e.g. interferons, such as IFN- $\gamma$  are also well known in the art, and will be discussed hereinbelow.

25 As used herein, "gamma interferon", "interferon- $\gamma$ " or "IFN- $\gamma$ " refers variously to all forms of (human and non-human animal) gamma interferons capable of activation of immune response against infection. The above terms are meant to specifically include IFN- $\gamma$  in a mature, pro, met or des(1-3) (also referred to as desCysTyrCys IFN- $\gamma$ ) form, whether obtained from natural source, chemically synthesized or produced by techniques of recombinant DNA technology.

30 In nature, the production of IFN- $\gamma$  is induced in T lymphocytes by foreign antigens to which the T cells are sensitized. Under certain conditions, natural killer (NK) lymphocytes may also produce IFN- $\gamma$ . The recombinant production of IFN- $\gamma$  was first reported by Gray, Goeddel and co-workers [Gray *et al.*, Nature 295, 503-508 (1982)], and is the subject of U.S. Patent Nos. 4,762,791, 4,929,544, 4,727,138 and 4,925,793. The recombinant IFN- $\gamma$  of Gray and Goeddel, as produced in E. coli, consisted of 146 amino acids, the N-terminal portion of the molecule commencing with the sequence CysTyrCys. It has later been found that the native IFN- $\gamma$  (i.e., that arising from mitogen induction of human peripheral blood lymphocytes and subsequent purification) is a polypeptide which lacks the CysTyrCys N-terminus assigned by Gray *et al.*, supra.

Non-human animal interferons, including  $\gamma$ , are, for example, disclosed in EP 88,622 published 14 September 1983.

5 The terms "gamma interferon", "interferon- $\gamma$ " or "IFN- $\gamma$ " include variously glycosylated forms and other variants and derivatives of such interferons, whether known in the art or will become available in the future. Examples of such variants are alleles, and the products of site directed mutagenesis in which residues are deleted, inserted and/or substituted (see, for example, Patent Application EP 146,354, published 26 June 1985).

10 The antiviral activity of interferons, and in particular IFN- $\gamma$ , has been demonstrated against a large number of viruses, in numerous in vitro and in vivo models.

15 Neumann-Haefelin *et al.*, Med. Microbiol. Immunol. **174**, 81 (1985) found that recombinant human IFN- $\gamma$  (rHuIFN- $\gamma$ ) prevented Herpes simplex (HS) keratitis in African green monkeys.

20 Van der Meide *et al.*, Antiviral Research, Suppl. 1, 199 (1985) compared the in vivo antiviral effects of human IFNs- $\alpha$ , - $\beta$  and - $\gamma$  on vaccinia virus infection in rhesus monkeys.

25 Infection was monitored by observation of skin lesions (appearance and diameter of papules and pustules). The results showed significant reduction in lesion severity for the groups intramuscularly treated with natural or recombinant HuIFN- $\gamma$ .

30 The in vivo antiviral activity of recombinant murine IFN- $\gamma$  (rMuIFN- $\gamma$ ) was, for example, evaluated by Shalaby *et al.*, J. Interferon Research **5**, 339 (1985), in a murine model of encephalomyocarditis (EMC) virus infection. The results demonstrated the ability of rMuIFN- $\gamma$  to protect mice against EMC virus infection. Similar results were reported by Sim, I.S. and Cerruti, R.L., Antiviral Res. **8**, 209 (1987).

35 Treatment with rMuIFN- $\gamma$  prior to infection with cytomegalovirus (MCMV) was reported to significantly reduce mortality in a murine model [Fennie *et al.*, Antiviral Res. **10**, 27 (1988)].

40 Further studies examined the efficacy of various immunomodulators, including rMuIFN- $\gamma$  in mouse models of experimental infection with Herpes simplex type 2 (HSV-2) virus, Banzi flavi virus, Venezuelan equine encephalitis (VEE) virus, and Caraparu bunya virus [Pinto *et al.*, Intern. J. Immunopharmacology **10**, 197 (1988)].

45 The efficacy of recombinant rat IFN- $\gamma$  (rRatIFN- $\gamma$ ) against pseudorabies virus (PRV) infection in immunologically impaired and immunosuppressed rats was demonstrated by Schijns *et al.*, J. Gen. Virol. **69**, 1979 (1988).

50 Although the mechanism by which the interferons produce their antiviral actions is not entirely understood, it is known that instead of directly inactivating viruses, they act indirectly through virus-susceptible cells. The wide antiviral range of interferons, including IFN- $\gamma$ , is thought to be due to their ability to modulate multiple biochemical pathways that have different antiviral effects and act on different parts of the viral replication cycles [Pestka *et*

*et al.*, Ann. Rev. Biochem. **56**, 727 (1987); Samus, C.E., Prog. Nucl. Acid Res. Mol. Biol. **35**, 27 (1988); Jacobsen, H., Arzneim. Forsch. Drug Res. **36**, 512 (1986)).

Numerous studies have demonstrated the ability of interferons to control, and particularly to prevent bacterial infections.

5 rMuIFN- $\gamma$  and rRatIFN- $\gamma$  were tested and found efficacious in various simulated wound bacterial infection models, including surgically stimulated and burn wound infection models [Hershman *et al.*, Clin. Exp. Immunol. **72**, 406 (1988); Hershman *et al.*, Microbial Pathogenesis **4**, 165 (1988); Hershman *et al.*, J. Interferon Res. **8**, 367 (1988)]. The use of IFN- $\gamma$  for the treatment of trauma-associated sepsis is reported by Herman, M.J. *et al.*, Infection and Immunity **56**, 2412 (1988).

10 IFN- $\gamma$  was, for example, shown to be efficacious in the prophylaxis and treatment of Klebsiella pneumoniae, Pseudomonas aeruginosa, Staphylococcus aureus, Chlamydia trachomatis, Mycobacterium intracellulare, Mycobacterium tuberculosis, Francisella tularensis, Salmonella typhimurium, Lysteria monocytogenes infections, in various in vitro and in vivo models of infection.

15 Although not completely understood, the mechanism of action of interferons, e.g. IFN- $\gamma$  is believed to involve a reduced ability of the bacteria to enter interferon treated cells.

20 The parasitic infections successfully controlled (prevented and/or treated) by IFN- $\gamma$  include Leishmania donovani infections [see e.g. Murray *et al.*, J. Clin. Invest. **83**, 1253 (1989)] and Toxoplasma gondii [McCabe *et al.*, J. Infect. Dis. **150**, 961 (1984)], and malaria in various Plasmodium infection models.

25 In vitro data suggest that immune cells (macrophages, neutrophils, etc.) are activated by incubation with IFN- $\gamma$  to kill fungi (C. albicans, H. capsulatum, B. dermatitis, P. brasiliensis) by oxidative as well as non-oxidative mechanisms as efficiently as other classes of microbial pathogens [see e.g. Brummer *et al.*, J. Immunol. **140**, 2786 (1988)]. Shear *et al.*, J. Acquired Immune Deficiency Syndromes **3**, 943 (1990) reported the efficacy of IFN- $\gamma$  in the prophylaxis and treatment of steroid-induced Pneumocystis carinii (an organism occasionally referred to as a parasite) pneumonia (PCP) in rats.

30 The recent knowledge of the mechanisms of action and clinical application of interferons, including IFN- $\gamma$  is summarized by Baron *et al.*, in JAMA **266**, 1375 (1991).

35 IFN- $\gamma$  is known to have a narrow host range, therefore, IFN- $\gamma$  homologous to the animal to be treated should be used. In human therapy, the desCysTyrCys variant of the sequence shown, for example, in United States Patent No. 4,717,138, and its counterpart EP 77,670 (published 27 April 1983) is preferably employed, and optionally the C-terminal truncated variant in which the last 4 residues are deleted in post-translational processing.

"Interleukin-2" or "IL-2" (originally named T cell growth factor) was first described by Morgan, D.A. *et al.*, Science **193**, 1007 (1976). The production of IL-2 by cultivating human peripheral blood lymphocytes (PBL) is, for example, described in U. S. Patent No. 4,401,756.

The recombinant production of IL-2 is, for example, reported by Taniguchi *et al.*, Nature **302**, 305 (1983) and Devos *et al.*, Nucleic Acid Res. **11**, 4307 (1983). "Interleukin-2" or "IL-2" refers variously to all forms of IL-2 as are known to be biologically active in accepted IL-2 assays, including alleles and variants obtained by substitution, insertion or deletion of one or 5 more amino acids in the native amino acid sequence, for example as described in U.S. Patent No. 4,518,584. The antimicrobial activity of IL-2 is, for example, described in PCT Applications Publication Nos. WO 85/05124 (published 21 November 1985) and WO 85/03948 (published 12 September 1985), EP 147,819 (published 10 July 1985), EP 118,617 (published 19 September 1984), EP 118,977 (published 19 September 1984), EP 10 132,754 (published 13 February 1985), EP 94,317 (published 16 November 1983), and in U.S. Patent Nos. 4,407,945 and 4,473,642.

15 "Tumor necrosis factor- $\alpha$ " or "TNF- $\alpha$ " was first described by Carswell *et al.*, Proc. Natl. Acad. Sci. USA **72**, 3666 (1975). The production of TNF- $\alpha$  by recombinant DNA technology was reported by Pennica *et al.*, Nature **312**, 724 (1984), and is, for example, disclosed in EP 168,214 (published 15 January 1986).

The treatment of bacterial infections in mammalian hosts with lymphokines, and specifically with TNF- $\alpha$  alone or in combination with IL-2 or with IFN- $\gamma$  is described in U.S. Patent No. 4,879,111.

20 The term "immunosuppressed" patient is used to denote a patient with impaired host defenses who is at risk of developing opportunistic infections. In transplant patients immunosuppression is the result of immunosuppressive therapy which is unavoidable for the successful performance of transplantation.

25 The terms "transplantation" and "transplant" are used herein in the broadest sense, and include solid and non-solid organ and tissue transplantations and transplants, such as liver, heart, kidney, and heterologous and autologous bone marrow transplantations/transplants.

30 The term "immunosuppressive therapy" is used in the broadest sense, and may involve the administration of immunosuppressive drugs (also referred to as "immunosuppressants"), such as cyclosporins, corticosteroids, cytotoxic immunosuppressants, antilymphocyte globulins, but also covers irradiation and associated chemotherapy. The particular immunosuppressive therapy is dependent on the nature of transplant.

35 Typical immunosuppressive therapy used to avoid graft rejection in recipients of solid organ transplants involves the use of cyclosporins, corticosteroids, and further immunosuppressive agents such as azathioprine, cyclophosphamide, and methotrexate. Recipients of bone marrow transplants are usually subjected to extensive irradiation and chemotherapy prior to transplantation.

Corticosteroids such as prednisone and dexamethasone, are known to have the most global immunosuppressive effects, and are able to alter almost every aspect of the host defense system. They impair the mobilization, adherence, phagocytosis, and bactericidal

activity of neutrophils, monocytes, and macrophages, depress T- and B-lymphocyte activity, diminish production of interferons and other cytokines, and alter the gastrointestinal flora. Their greatest effect is on leukocyte responses. Steroid treatment greatly increases the patient's susceptibility to a variety of bacterial, viral, fungal, or parasitic infections, and 5 activates latent endogenous infections. According to clinical practice, high doses of steroids are usually well tolerated up to about three weeks, but after that the incidence of various, often life threatening, infections substantially increases.

10 Immunosuppressive agents often used in combination with corticosteroids, including cyclophosphamide, azathioprine and methotrexate, are also known to produce defects in host defenses and to enhance the risk of infectious complications.

15 "Cyclosporins" are a group of biologically active metabolites produced by Tolyphocladium inflatum Gams and other fungi imperfecti. The major components, cyclosporins A and C, are non-polar cyclic oligopeptides with immunosuppressive properties. In particular, Cyclosporin A (CsA) is widely used in clinical practice as immunosuppressant. Synthetic cyclosporin analogues, such as Cyclosporin G (CsG) [Sandoz, Inc.; see McKenna et al., Transplantation (USA) 47, 343-348 (1989)], (Nvasup 2)-CS and (Valsup 2)DH-CS [Hiestand et al., Immunology 55, 249-255 (1985)] are also known. The term "cyclosporin" as used throughout the specification and claims includes all naturally occurring cyclosporins and their synthetic analogues and derivatives, either known in the art or hereinafter produced, 20 provided that they have immunosuppressive properties similar, in kind, to those of Cyclosporin A. Cyclosporins are advantageous in that they are more specific in their action than corticosteroids. Their activity appears to be specifically directed against the T-lymphocyte helper/inducer lymphocyte subpopulation, without any direct effect on functioning B-cells, monocytes, macrophages, neutrophils and natural killer (NK) cells.

25 Radiation therapy (like cytotoxic drugs) has the greatest effect in suppressing the development of new immune response. Although, if the treatment is carefully administered, infections that can be directly attributed to radiation therapy are relatively rare, total body irradiation often results in granulocytopenia.

According to clinical experience, the cumulative effects of various immunosuppressive 30 therapies/agents may far exceed the effects of each treatment alone.

A typical prophylactic (pre-operative and maintenance) immunosuppressive protocol used in renal (and with some modifications in heart) transplant patients includes the administration of Cyclosporin A, azathioprine and corticosteroids. According to a representative protocol, Cyclosporin A is administered orally, in a pre-operative dose of 12 mg/kg, while the initial post-operative dose is 8 mg/kg/day, and is adjusted by blood level. 35 Following the same protocol, azathioprine is administered in a pre-operative i.v. dose of 3 mg/kg and in a post-operative dose of 1.5 mg/kg/day, which is decreased if the white blood count (WBC) drops below 3,000. The daily dose of steroids is 2 mg/kg/day on days 0, 1 and

2, and is gradually decreased to about 0.15 mg/kg/day, which is typically reached at or about day 120.

5 In some situations, an anti-lymphocyte preparation (e.g. anti-CD3 [OKT3], anti-CD4 [OKT4], anti-CD8, anti-CD11a, 11b, or 11c, anti-CD18, anti-lymphocyte globulin, anti-IL-2 receptor) is administered to the patient immediately after transplantation. This permits the discontinuance of cyclosporin administration, and some experts believe may induce partial tolerance of the graft. The risk of infection, particularly Cytomegalovirus (CMV) and Epstein-Barr virus (E-B) associated lymphoproliferative syndromes, is very high in this situation.

10 When rejection of the transplant is diagnosed by biopsy, clinical impression or any other diagnostic method known in the art, anti-rejection therapy is initiated. This might include the administration of high doses of steroids, anti-lymphocyte therapy or their combination. For example, renal transplant recipients are typically treated with a 500 mg/kg/day intravenous dose of Solumedrol (methylprednisolone 21-succinate sodium salt, Upjohn) for four days following the diagnosis of mild rejection. If the rejection is moderate 15 or severe, an anti-CD3 [OKT3] murine monoclonal antibody (Orthoclone) may, for example, be administered in a 5 mg/day i.v. dose for about 10 to 14 days.

20 It will be understood that although the prophylactic and anti-rejection protocols outlined above are typical of many transplant centers, treatment may considerably vary by program philosophy, the type of organ transplanted, and the patient's condition. For example, the maintenance dose of cyclosporin may vary from about 1 to about 20 mg/kg/day. The doses required for liver and heart transplants are usually higher than for kidney and bone marrow transplants. The use of lymphokines, and particularly IFN- $\gamma$  for the prophylaxis or treatment of microbial infections in transplant patients is envisioned in conjunction with any of the prophylactic or anti-rejection protocols used in the clinical practice. In transplant patients, 25 who do not receive anti-lymphocyte prophylaxis, and are administered cyclosporin and high doses of steroids, lymphokine (IFN- $\gamma$ ) administration should typically be initiated at the time of transplantation, and should typically be maintained up to about 40 days thereafter. In patients receiving prophylactic antilymphocyte therapy, the administration of lymphokines (e.g. IFN- $\gamma$ ) can typically be initiated at the time of transplantation and continued for about 30 7 to 21 days after the anti-lymphocyte therapy is concluded. When the monitoring of patient suggests that rejection is occurring, lymphokine (IFN- $\gamma$ ) administration can be initiated parallel with conventional immunosuppressive therapy (e.g. high doses of steroids) and should be maintained for at least about two weeks, to prevent infections associated with impaired immune response.

35 The lymphokines, such as IFN- $\gamma$ , IL-2, as well as the immunosuppressants, such as cyclosporins are usually administered in the form of pharmaceutical compositions comprising an effective amount of the active ingredient in admixture with a suitable pharmaceutically acceptable vehicle and optionally other pharmaceutically acceptable additives.

The term "pharmaceutical composition" refers to preparations which are in such form as to permit the biological activity of the active ingredients to be unequivocally effective, and which contain no additional components which are toxic to the subjects to which the composition would be administered. Such pharmaceutical compositions may be prepared and 5 formulated in dosage forms by methods known in the art; for example, see Remington's Pharmaceutical Sciences, Mack Publishing Company, Easton, Pennsylvania, 15th Edition 1975.

"Pharmaceutically acceptable" excipients (vehicles, additives) are those which can reasonably be administered to a subject mammal to provide an effective dose of the active 10 ingredient employed. Typical vehicles include saline, dextrose solution, Ringer's solution, etc. but non-aqueous vehicles may also be used.

15 Lymphokines may be administered to a subject mammal, such as human, via any of the accepted modes of administration for such agents, including subcutaneous and parenteral administration. Examples of parenteral administration routes are intravenous, intrapulmonary, intraarterial, intramuscular, and intraperitoneal administration. The actual route of administration will depend on a number of considerations, including the nature of infection to be treated, if the administration is initiated after the onset of infection. Usually 20 subcutaneous or intravenous administration is preferred, but for the treatment of lung (*P. carinii*) infections intrapulmonary administration may be best suited.

25 For parenteral administration, the lymphokines are generally formulated in a unit dosage injectable (e.g. solution, suspension, emulsion) form.

30 The formulation of IFN- $\gamma$  is preferably liquid, and is ordinarily a physiological salt solution or dextrose solution, together with conventional stabilizers and/or excipients. IFN- $\gamma$  compositions may also be provided as lyophilized powders. A typical formulation may contain 35 IFN- $\gamma$  ( $20 \times 10^6$  U) at 1.0 or 0.2 mg/ml, 0.27 mg/ml succinic acid, and disodium succinate hexahydrate 0.73 ml/injection at pH 5.0. Preferred liquid formulations comprising non-lyophilized IFN- $\gamma$  are disclosed in PCT WO89/4177 published 18 May 1989. Such liquid formulations have a pH of about 4.0 to 6.0 and comprise a stabilizing agent and a non-ionic detergent. For intrapulmonary delivery, IFN- $\gamma$  is typically administered as a dispersion comprising a therapeutically effective amount thereof. The dispersion preferably is an aerosol formulation, in which greater than about 15% of the particles have a particle size of from about 0.5  $\mu$ m to about 4  $\mu$ m (see EP 257,956 published 3 February 1988).

40 IFN- $\gamma$  is preferably administered according to the present invention subcutaneously at doses from about 0.01 to about 0.1 mg/m<sup>2</sup>/day as long as necessary to treat the infection. 45 The frequency of administration varies depending on the nature of infection, and the patient's condition, and preferably is between daily and once a week.

IL-2 containing pharmaceutical compositions suitable for reconstitution in a pharmaceutically acceptable aqueous vehicle are disclosed in PCT Application Publication No. WO 85/04328.

5 In a pharmacological sense, in the context of the present invention, an "effective amount" of a lymphokine, such as IFN- $\gamma$  and/or IL-2 refers to an amount effective in control of microbial infections. In this context, the term "control" is used to include both prophylaxis and treatment of such infections. Accordingly, IFN- $\gamma$  may be administered prophylactically (i.e. prior to the appearance of the infection), or therapeutically (i.e. after appearance of the infection), the prophylactic application being preferred.

10 The determination of the exact doses in view of the patient's condition, and the desired frequency is well within the skill of a skilled artisan. Immunologically effective doses may generally be determined for a particular application according to the procedure of Maluish et al., J. Clin. Oncol., 6, 434-435 (1988).

15 The term "microbial infection" and its grammatical variants are used to refer to any infections occurring in transplant patients that can be controlled by lymphokine, e.g. IFN- $\gamma$  or IL-2 treatment. Such microbial infections are primarily the opportunistic infections stemming from the depressed immunity of transplant recipients due to immunosuppressant treatment, also common in other immunocompromised hosts such as AIDS patients [Gottlieb, et al., Ann. Intern. Med., 99, 208 (1983); Periti, P. and Mazzei, T., Clinical Therapeutics 8, 20 100 (1985)]. Opportunistic pathogens that frequently cause infectious complications in immunocompromised patients are bacteria, such as Staphylococcus aureus, Streptococci, Pseudomonas aeruginosa, Escherichia coli, Klebsiella pneumoniae, Haemophilus influenzae, Legionella pneumophila, Salmonella species, Aeromonas hydrophila, Marine vibrios (halophilic), Nocardia species, Mycobacterium tuberculosis; fungi, such as Candida species, 25 Torulopsis species, Aspergillus species, Zygomycetes, Cryptococcus neoformans, histoplasma capsulatum; viruses, such as Herpes simplex, Varicella zoster, Cytomegalovirus (CMV), Epstein-Barr (E-B) virus, Hepatitis B virus; parasites, such as Toxoplasma gondii, Strongyloides stercoralis, Pneumocystis carinii (the latter organism is also thought to be a fungus) [Periti, P. and Mazzei, T., "Infections in Immunocompromised Patients" in Clin. Ther. 8, 100-117 30 (1985) and Ho, M., "Human cytomegalovirus infections in immunosuppressed patients." In: Cytomegalovirus: Biology and Infection, 171-204, Plenum Press, New York, (1982)]. A common clinical presentation of such infections is the occurrence of pneumonia caused by Pneumocystis (P.) carinii, or Legionella species; however, other usual bacterial (Salmonella species, Yersinia monocytogenes), mycobacterial, fungal and protozoa infections, listed above 35 or otherwise known, can also be prevented or treated with IFN- $\gamma$  in accordance with the present invention.

The potentials of IFN- $\gamma$  in the treatment microbial infections in immunocompromised transplant recipients are supported by reports that in addition to its profound effect on

immune responses, IFN- $\gamma$  enhances phagocytosis, oxidative capacity, chemotaxis and microbial capacity of monocytes and macrophages *in vitro* from patients with AIDS [Murray *et al.*, *N. Engl. J. Med.* **310**, 883 (1984)].

Some of the above-listed and further microbial infections are also directly associated with the surgical trauma of transplantation. Such trauma-associated infections typically include bacterial infections caused by Gram-positive bacteria, such as *Staphylococcus aureus*, *Streptococcus faecalis*, Pneumococci, anhaemolytic Enterococci, *Sarcina* species, and haemolytic Streptococci; and Gram-negative bacteria such as *Escherichia coli*, *Pseudomonas* species, *Klebsiella* species, *Proteus* species, *Enterobacter cloacae*, coliform bacteria, *Serratia* species, *Citrobacter* species, and *Providencia* species [Allgower *et al.*, *Surg. Clin. N. Am.* **60**, 133-144 (1980)].

Lymphokines, and specifically IFN- $\gamma$ , can be co-administered with each other and other antimicrobial agents or therapeutics used in the treatment of transplant patients. Co-administration includes simultaneous or successive administration. Oral antimicrobial agents that, despite suppression of aerobic flora, preserve colonization resistance include, for example, co-trimoxazole, nalidixic acid, oxolinic acid, pipemidic acid, framycetin, polymyxin B, colistin, nystatin, amphotericin B, clotrimazole, miconazole, ketokonazole. Prophylaxis with co-trimoxazole has, for example, become a standard procedure in patients at high risk of acquiring *P. carinii* pneumonia [Russe *et al.*, *J. Antimicrob. Chemother.* **8**, 87 (1981)]. Oral antimicrobial agents that decrease colonization resistance include, for example, aminoglycosyldase antibiotics, e.g. neomycin, paromomycin, kanamycin, bekamycin, ribostamycin, dibekacin, tobramycin, amikacin, gentamicin, sisomicin, netilmicin, bacitracin, vancomycin. Aminoglycosidase antibiotics are usually administered with a beta-lactam (penicillin and/or cephalosporin) antibiotic. Penicillin antibiotics include penicillin, carbenicillin, ampicillin, amoxacillin, methicillin, oxacillin, cloxacillin, dicloxacillin, nafcillin, thienamycin, piperacillin, azlocillin, mezlocillin, etc. Cephalosporin antibiotics include, e.g. cephalexin, cephadrine, cefaclor, cefadroxil, ceftrizine, cefaparole, cefroxadine, cephalothin, cephaloridine, cefalozin, cefonicid, cefametazole, etc. The antimicrobial therapy herein may be combined with the administration of any of such known antimicrobial agents and further therapeutics traditionally used in the treatment of transplant patients. For further details see Periti, P. and Mazzei, T., *supra* and Cushing, *Surg. Clin. N. Am.* **57**, 165 (1977).

Further details of the invention are illustrated in the following non-limiting Examples.

#### Example 1

##### Administration of IFN- $\gamma$ to Heart Transplant Recipients

35 I. Materials and Methods

Rats Lewis strain rats and AC strain rats (200-250 g) were obtained from Charles River Laboratories, Portage, MI.

Transplantation procedure All rats were anesthetized with 10% phenobarbital sodium solution. The Lewis strain rats each received 1 mg of gentamicin via the intramuscular route. AC rats received 100 units of heparin intravenously. The heart was removed from the AC rat, flushed through the aorta with saline at 4°C, and placed into an iced saline solution.

5      Heterotopic transplantation of the AC rat heart into the abdomen of the Lewis rat was carried out by the technique of Ono and Lindsey [*J. Thorac. Cardio. Surg.* **57**, 15 (1969)]. Standard recovery procedures were used, and the animals were examined daily for palpable heart beat. Rejection was considered complete on the last day the heart beat was palpable. The animals were sacrificed on the day following rejection, or, if there was no rejection, 20 or 45 days

10     after the transplantation took place. Transverse sections of the midportion of the right and left ventricular chambers were stained with hematoxylin and eosin. Slides were examined and a histologic rejection score from 0 - 10 was assigned using the Texas Heart Institute rejection scale [McAllister, *et al.* *Texas Heart Inst. J.* **13**, 1 (1986)] by a pathologist experienced in grading heart transplantation rejection and blinded completely to the

15     experimental protocol.

Cyclosporin treatment All transplanted rats received a dose of 20 mg/kg/day on the day of transplantation as well as 1 and 2 days post-transplantation. This dose controls rejection so that the heart transplants are rejected 45 days post-transplantation [Hershman, *et al.* *Infec. Immun.* **56**, 2412 (1988); and Clifford, D.P. & Repine, J.E., *Methods Enzymol.* **105**, 393 (1984)]. Some transplanted rats received additional "maintenance" cyclosporin treatment of 8 mg/kg/day by gavage feeding beginning on day 3 post-transplantation and continuing throughout the experiment.

20     IFN-γ treatment Recombinant rat IFN-γ was purchased from Amgen Biologicals, Thousand Oaks, CA, and had a specific activity of  $4 \times 10^8$  units/mg protein. IFN-γ was given to the rats as described for each individual experiment.

25     Measurement of oxidative burst Neutrophils were separated from whole blood of the rats by density centrifugation using 1119 isolation medium (Sigma Chemical Company, St. Louis, MO). F-Met Leu-Phe (FMLP) was used to trigger respiratory burst, and the production of superoxide was measured by fluorometric methods [Clifford *et al.*, *Methods Enzymol.* **105**, 393 (1984)].

30     Statistical analysis When sample sizes for each group were equal, the Student *t* Test was used for analysis of the data. When sample sizes were different, the Behrens-Fisher *t* Statistic with the Welsh *df* correction was used for analysis of the data.

35     All experimentation was carried out in compliance with the "principles of Laboratory Animal Care" formulated by the National Society for Medical Research. All animals were housed in an AAALAC facility under NIH guidelines under the direct supervision of a veterinarian.

II. Effect of IFN- $\gamma$  on rejection of the heart transplant

5 Lewis strain recipient rats were received 20 mg/kg/day of cyclosporin on the day of transplant and for two days following transplantation. The heart of an AC strain rat was transplanted into the abdomen of each recipient. The rats in the control group did not receive any additional treatment. The 20 mg/kg/day dose of cyclosporin administered as described is known to control rejection so that hearts are rejected 45 days post-transplantation (Hershman, et al., supra).

10 Experimental rats each received 750 units of IFN- $\gamma$  per day via the intramuscular route on the day of transplant and for 3 additional days. The results set forth in Table 1 show that the rats treated with IFN- $\gamma$  showed a much accelerated rejection compared to controls.

Table 1Effect of IFN- $\gamma$  treatment on retention of heart transplants by rats

	<u>Treatment</u>	<u>N</u>	<u>Mean Days to Rejection</u>	<u>P</u>
15	Control	10	44.7	-
	750U IFN- $\gamma$	5	11.0	<0.05

20 (In a third group, transplantation was performed on Lewis strain recipient that did not receive cyclosporin, and were administered IFN- $\gamma$  as described above. This group could not be evaluated because of early rejection.)

III. Effect of maintenance doses of cyclosporin on IFN- $\gamma$  mediated enhanced rejection of the heart transplant.

A. Effect of maintenance doses of cyclosporin on rejection of transplanted hearts  
25 Each of the Lewis strain recipient rats received 20 mg/kg/day of cyclosporin on the day of transplantation as well as one and two days post-transplantation. The rats received additional "maintenance" doses of 8 mg/kg/day cyclosporin beginning on the 3rd day after transplantation and continuing throughout the course of the experiment. Groups of rats were sacrificed 20 days or 45 days post-transplantation. No difference in histological mean rejection score was noted at 20 and 45 days post-transplantation, as shown in Table 2.

Table 2

## Effect of "maintenance" cyclosporin on rejection of transplanted hearts

	<u>Time of Sacrifice</u>	<u>N</u>	<u>Mean Rejection Score</u>	<u>P</u>
35	20 days post-transplant	10	1.0	-
	45 days post-transplant	10	1.2	NS

NS = not significant

Effect of maintenance cyclosporin treatment on IFN- $\gamma$  enhanced rejection of heart transplants

All rats received 20 mg/kg/day cyclosporin beginning on the day of transplantation and continuing for two additional days. The rats also received "maintenance" doses of 8 mg/kg/day of cyclosporin beginning on the third day post-transplantation and continuing until sacrifice. Experimental rats were treated with either 750 units/day or 7500 units/day of IFN- $\gamma$  via the intramuscular route starting on the day of transplantation and for three additional days. Transplanted hearts did not show complete rejection (stop beating) throughout the course of the experiment i.e. the hearts were not rejected by 45 days post-transplantation.

Mean rejection scores were increased significantly only with the 750 units dose of IFN- $\gamma$  at 20 days, but there was no significant difference at 45 days after transplantation (Table 3).

Table 3

Effect of "maintenance" cyclosporin treatment on IFN-gamma enhanced rejection of heart transplants

15	<u>Treatment</u>	<u>MRS (20 Days)</u>	<u>N</u>	<u>P</u>	<u>NRS (5 Days)</u>	<u>N</u>	<u>P</u>
	None	1.0	10	-	1.2	10	-
	750U IFN- $\gamma$	3.0	10	<0.05	1.5	5	NS
	7,500U IFN- $\gamma$	2.9	5	NS	2.2	4	NS

20 MRS = mean rejection score, using the Texas Heart Institute scoring method for endomyocardial biopsies. Grades 1-3: mild; 4-6: moderate; and 7-10: severe. [see McAllister *et al.*: A system for grading cardiac allograft rejection. Texas Heart Institute J. 13, 1 (1986)].

NS = not significant.

25

IV. Effect of "maintenance" cyclosporin treatment on IFN- $\gamma$  mediated induction of oxidative burst of neutrophils by FMLP

Lewis rats on the "maintenance" cyclosporin regimen described above received a heart transplant from AC rats. All rats received 20 mg/kg/day cyclosporin beginning on the day of transplantation and continuing for 2 additional days. The rats also received a "maintenance" dose of 8/mg/kg/day cyclosporin beginning on the third day of post-transplantation and continuing until sacrifice of the animals, and were sacrificed 4 days post-transplantation. The rats received a high dose of 75,000 units of IFN- $\gamma$  via the intramuscular route starting on the day of transplantation and for three additional days. After four days, the rats were sacrificed and bled, and their neutrophils were tested for the IFN- $\gamma$  mediated FMLP-induced oxidative burst. Two experiments were performed using two rats each. The data presented in Table 4 suggest that the "maintenance" cyclosporin did not inhibit the IFN- $\gamma$  mediated production of superoxide by neutrophils.

Table 4

Effect of "maintenance" cyclosporin treatment on FMLP induced oxidative burst of neutrophils from animals that received IFN- $\gamma$

<u>Treatment</u>	<u>N</u>	<u>Superoxide Generated (nm/10<sup>6</sup> Cells)</u>
5 Control	2 (in duplicate)	0.68
75,000 u IFN- $\gamma$	2 (in duplicate)	3.70

V. Discussion

Treatment of rats with a heterologous heart-transplant with IFN- $\gamma$  has been shown to increase the rate of rejection of the heart in the current study. The time to rejection was decreased from 44.7 days to 11 days. This suggests that IFN- $\gamma$  treatment for infection during transplantation could affect dramatically the outcome of the transplantation. The enhanced rejection could be due to increased induction of histocompatibility antigens, particularly class II histocompatibility antigens, by the IFN- $\gamma$  treatment. However, since IFN- $\gamma$  has a multitude of immunoregulatory activities, it is possible that the IFN- $\gamma$  could be affecting rejection by other, as yet undefined, mechanisms. The mechanisms of how IFN- $\gamma$  enhances rejection remain to be established in future studies.

In any case, the results of the current study suggest that the potential deleterious effects of utilizing IFN- $\gamma$  in transplant patients can be avoided. Use of continuous, low "maintenance" doses of cyclosporin throughout the study period, as carried out for extended periods of time on most transplant patients, resulted in an abrogation of the deleterious effects of the IFN- $\gamma$  treatment on the transplanted heart. Therefore, it is possible to administer IFN- $\gamma$  to transplanted individuals via a systemic route without inducing rejection of the transplanted tissue. This makes even more attractive the potential use of IFN- $\gamma$  administration via a local route (such as aerosolization) to transplant patients.

Since cyclosporin is a generally immunosuppressive drug, the question could be asked: if "maintenance" cyclosporin treatment results in abrogation of IFN- $\gamma$ -induced enhanced heart transplant rejection, does it also abrogate the beneficial antimicrobial effects of the IFN- $\gamma$  treatment? The results of the present study suggest that this is not the case. "Maintenance" cyclosporin therapy did not alter the enhanced FMLP-induced oxidative burst of neutrophil from animals that had received IFN- $\gamma$ . Since the neutrophil is a major cell for combatting infections, these results suggest that at least some of the positive anti-microbial benefits of the potential IFN- $\gamma$  treatment of transplanted individuals would be retained using "maintenance" cyclosporin therapy.

Example 2The effect of IFN- $\gamma$  in the mouse autologous bone marrow transplant model

In this model, adult male CBA/J mice, weighing 20-25 g each, (Jackson Laboratories, 5 Bar Harbor, Maine) are lethally irradiated with 900 rads of X-irradiation. The mice are then reconstituted on the same day with approximately  $1 \times 10^7$  bone marrow cells obtained from the femurs and tibia of normal CBA/J donor mice. The mice are maintained on acidified water in a clean environment, and several survive for at least 2-3 weeks after transplantation. The 10 mice receive 20 mg/kg/day cyclosporin beginning on the day of bone marrow transplantation and continuing for two additional days. The mice also receive "maintenance" doses of 8 mg/kg/day of cyclosporin beginning on the third day post-transplantation and continuing until sacrifice. Experimental mice are treated with either 750 units/day or 7500 units/day of 15 recombinant murine IFN- $\gamma$  (a gift of Genentech, Inc., South San Francisco, California. The specific activity of this IFN- $\gamma$  is approximately  $2.3 \times 10^7$  units/mg protein and is diluted with RPMI-1640 medium (Gibco Laboratories, Grand Island, New York) via the intramuscular route starting on the day of bone marrow transplantation and for three additional days. In one set 20 of experiments, survival of the mice is determined over a three-week period. Peripheral complete blood counts are performed on a regular basis to determine success of engraftment. In addition, members of the IFN- $\gamma$  treated and of the control groups are sacrificed 1-2 times 25 weekly, and bone marrow examined for success of engraftment. When the animals die, they are examined for evidence of infection. Levels of Ia antigen expression on peripheral blood lymphocytes are determined by specific-antibody staining and flow cytometry one day prior to transplant and on days 1, 7, and 14 post-transplant. A comparison of the complete blood count and survival rate between control and treated groups shows the effect of IFN- $\gamma$  treatment on the course of autologous bone marrow transplantation.

Example 3The effect of IFN- $\gamma$  treatment on exogenously induced infection in transplant patients

The ability of IFN- $\gamma$  treatment to affect the survival rate of transplanted rodents that 30 are infected deliberately is examined in the cardiac allograft and autologous bone marrow transplant models described in Examples 1 and 2. Lengths of 3-0 twisted cotton suture are incubated overnight in trypticase soy broth (BBL Microbiological Systems, Cockeysville, Maryland) and inoculated with Klebsiella pneumoniae (Capsular Type 2). On the third day 35 after transplantation, lengths of suture attached to a French eye needle are inserted aseptically into the right thigh of each rodent and the suture is cut flush with the skin at either end buried subcutaneously. A group of transplanted rodents in each model are treated with IFN- $\gamma$  essentially as described in Examples 1 and 2 hereinabove. Another group is sham-treated with diluent. Rodents are monitored for 2-3 weeks. Bacterial blood cultures are

carried out on alternate days. Uninfected transplanted rodents serve as a control to insure that complications of transplantation procedure are not responsible for animal mortality. Efficacy of IFN- $\gamma$  treatment is determined by observation of increased survival and by analysis of blood cultures. At the time of death, all animals undergo necropsy with careful examination for signs of pneumonitis, peritonitis, and endocarditis.

5 The foregoing description details methods and compositions representative of the present invention. It is understood that modifications and variations are possible without departing from the general concept of the present invention, and that such modifications are intended to be within the scope of the present invention.

## Claims.

1. The use of an antimicrobial lymphokine in the manufacture of a medicament for the prophylaxis or treatment of microbial infections in transplant recipients.
2. The use according to claim 7 wherein at least one causative organism of said microbial infection is bacterial, fungal, viral or parasitic.
- 5 3. The use according to claim 1 or 2 wherein the recipients are subjected to maintenance immunosuppressive therapy following transplantation.
4. The use according to claim 3 wherein the antimicrobial lymphokine is interferon- $\gamma$  (IFN- $\gamma$ ) or interleukin-1 (IL-2) or a combination thereof, and the maintenance 10 immunosuppressive therapy comprises the postoperative administration of one or more immunosuppressants.
5. The use according to claim 4 wherein the antimicrobial lymphokine is IFN- $\gamma$ .
6. The use according to claim 5 wherein said immunosuppressants comprise a cyclosporin.
- 15 7. The use according to claim 6 wherein said cyclosporin is Cyclosporin A.
8. The use according to claim 7 wherein Cyclosporin A is administered in a postoperative dose of about 1 to 20 mg/kg of body weight/day.
9. The use according to any of claims 5 to 8 wherein IFN- $\gamma$  is for prophylactic administration.
- 20 10. The use according to any of claims 5 to 8 wherein said IFN- $\gamma$  is for administration in the form of a liquid pharmaceutical composition.
11. The use according to claim 10 wherein said liquid pharmaceutical composition has a pH of about 4.0 to 6.0, and comprises a stabilizing agent and a non-ionic detergent.
12. The use according to any of claims 5 to 8 wherein said IFN- $\gamma$  is for 25 ultrapulmonary delivery of a dispersion of a therapeutically effective amount thereof.
13. The use according to any of claim 5, 10 and 12 wherein said IFN- $\gamma$  is desCysTyrCys human IFN- $\gamma$ .
14. The use according to claim 13 wherein said IFN- $\gamma$  lacks the last four C-terminal amino acid residues.
- 30 15. The use of IFN- $\gamma$  in manufacture of a medicament for avoiding infection-associated graft rejection in transplant recipients subjected to maintenance immunosuppressive therapy following transplantation.
16. A method for the prophylaxis or treatment of microbial infections in transplant recipients comprising administering a therapeutically effective dose of an antimicrobial 35 lymphokine to said transplant recipients following transplantation under conditions such that the action of said lymphokine resulting in increased graft rejection is suppressed while retaining its antimicrobial activity.

17. The method according to claim 16 wherein the ability of said lymphokines to upregulate the cell-mediated component of the immune system is suppressed.
18. The method according to claim 16 wherein the lymphokine is interferon- $\gamma$  (IFN- $\gamma$ ).
19. The method according to claim 18 wherein the transplant recipients are 5 subjected to maintenance cyclosporin immunosuppressive therapy following transplantation.
20. The method according to claim 19 wherein IFN- $\gamma$  administration is initiated prior to the onset of microbial infection.
21. The method according to claim 20 wherein IFN- $\gamma$  administration is initiated within about 40 days following transplantation.
- 10 22. The method according to claim 21 wherein a biological response modifying level of a cyclosporin is maintained for at least the duration of IFN- $\gamma$  administration.
23. The method according to claim 19 wherein IFN- $\gamma$  administration is initiated subsequent to the onset of microbial infection.
- 15 24. The method according to claim 20 or 23 wherein the administration of IFN- $\gamma$  is maintained for about two weeks.
25. The method according to claim 19 wherein the transplant recipient is monitored for a parameter or symptom indicating the onset of a rejection episode.
26. The method of claim 25 wherein the administration of a steroid is initiated when said monitoring indicates the onset of rejection.

## INTERNATIONAL SEARCH REPORT

International Application No.

PCT/US 92/08479

I. CLASSIFICATION SUBJECT MATTER (If several classification symbols apply, list all)<sup>6</sup>

According to International Patent Classification (IPC) or to both National Classification and/or C

Int.C1. 5 A61K37/02; A61K37/66

## II. FIELDS SEARCHED

Minimum Documentation Searched<sup>7</sup>

Classification System	Classification Symbols			
Int.C1. 5	A61K ;	C07K ;	C12P ;	C12N

Documentation Searched other than Minimum Documentation  
to the Extent that such Documents are Included in the Fields Searched<sup>8</sup>III. DOCUMENTS CONSIDERED TO BE RELEVANT<sup>9</sup>

Category <sup>10</sup>	Citation of Document, <sup>11</sup> with indication, where appropriate, of the relevant passages <sup>12</sup>	Relevant to Claims No. <sup>13</sup>
X	<p>TRANSPLANTATION vol. 45, no. 2, February 1988, pages 402 - 405</p> <p>J. KOVARIK ET AL 'Adverse effect of low-dose prophylactic human recombinant leukocyte interferon-alpha treatment in renal transplant recipients' cited in the application * see the whole article especially page 402 right column and page 405 *</p> <p>---</p> <p>-/-</p>	1-3, 16

<sup>10</sup> Special categories of cited documents :<sup>10</sup><sup>11</sup> "A" document defining the general state of the art which is not considered to be of particular relevance<sup>12</sup> "E" earlier document but published on or after the international filing date<sup>13</sup> "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)<sup>14</sup> "O" document referring to an oral disclosure, use, exhibition or other means<sup>15</sup> "P" document published prior to the international filing date but later than the priority date claimed<sup>16</sup> "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention<sup>17</sup> "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step<sup>18</sup> "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art<sup>19</sup> "A" document member of the same patent family

## IV. CERTIFICATION

Date of the Actual Completion of the International Search

25 JANUARY 1993

Date of Mailing of this International Search Report

International Searching Authority

EUROPEAN PATENT OFFICE

Signature of Authorized Officer

LE CORNEC N.D.R.

## III. DOCUMENTS CONSIDERED TO BE RELEVANT (CONTINUED FROM THE SECOND SHEET)

Category	Citation of Document, with indication, where appropriate, of the relevant passages	Relevant to Claim No.
X	<p>JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION  vol. 266, no. 10, 11 September 1991,  pages 1375 - 1383  S. BARON ET AL 'THE INTERFERONS  mechanisms of action and clinical applications'  cited in the application  * the whole article especially page 1380  *</p> <p>---</p>	1-2
X	<p>TRANSPLANTATION PROCEEDINGS  vol. 19, no. 5, October 1987,  pages 4089 - 4095  K. TAKAHASHI ET AL 'Effect of human interferon-beta on life-threatening viral pneumonitis in kidney transplant recipients'  see the whole document</p> <p>---</p>	1-3, 16
A	<p>TRANSPLANTATION  vol. 45, no. 1, January 1988,  pages 76 - 81  R. M. MCKENNA ET AL 'Interleukin-2, interferon, and lymphotoxin in renal transplant recipients'  cited in the application</p> <p>-----</p>	

# INTERNATIONAL SEARCH REPORT

International application No.

PCT/US92/08479

## Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1.  Claims Nos.:

because they relate to subject matter not required to be searched by this Authority, namely:

Remark: Although claims 16-26 are directed to a method of treatment of the human/animal body the search has been carried out and based on the alleged effects of the compound/composition.

2.  Claims Nos.:

because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:

3.  Claims Nos.:

because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

## Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1.  As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.

2.  As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.

3.  As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid; specifically claims Nos.:

4.  No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

### Remark on Protest

The additional search fees were accompanied by the applicant's protest.

No protest accompanied the payment of additional search fees.

